Product
Supplier
Encyclopedia
Inquiry
Home > News > Pharma News
ECHEMI chemical news

Pharma News

FDA Shocking Approval of Kisqali: 25% Increased Recurrence Risk for Early Breast Cancer Patients, Treatment Risks Double?

FDA Shocking Approval of Kisqali: 25% Increased Recurrence Risk for Early Breast Cancer Patients, Treatment Risks Double?

2024-09-20

The benefit of invasive disease-free survival (iDFS) compared to receiving endocrine therapy (ET) alone was consistently observed in all patient subgroups 3-6.

FDA Grants Emergency Approval! Eli Lilly's IL-13 Inhibitor Ebglyss Poses New Crisis for Atopic Dermatitis Patients, Affecting Those Aged 12 and Older

FDA Grants Emergency Approval! Eli Lilly's IL-13 Inhibitor Ebglyss Poses New Crisis for Atopic Dermatitis Patients, Affecting Those Aged 12 and Older

2024-09-20

Eli Lilly recently announced that the U.S. Food and Drug Administration (FDA) has officially approved its IL-13 inhibitor Ebglyss (lebrikizumab).

U.S. 301 Tariffs Hit Hard: Chinese Medical Device Industry Faces 50%-100% Tariff Increase, Company Stock Prices Plummet

U.S. 301 Tariffs Hit Hard: Chinese Medical Device Industry Faces 50%-100% Tariff Increase, Company Stock Prices Plummet

2024-09-20

The Office of the United States Trade Representative has officially announced the final implementation of the 301 tariffs on Chinese goods, which will be implemented in phases on September 27, 2023, January 1, 2025, and January 1, 2026.

Povidone iodine solution first aid antiseptic: how does it work?

Povidone iodine solution first aid antiseptic: how does it work?

2024-09-20

Povidone iodine solution first aid antiseptic is a type of iodine tincture, used for skin disinfection and sterilization before and after surgery, prevention and treatment of local wound infections, and first aid for minor cuts, abrasions, burns, etc.

GlaxoSmithKline Vaccine Combination Trial Fails: Joint Vaccination Shows Mediocre Results, 177,000 Hospitalization Risk Unchanged!

GlaxoSmithKline Vaccine Combination Trial Fails: Joint Vaccination Shows Mediocre Results, 177,000 Hospitalization Risk Unchanged!

2024-09-19

The trial evaluated two of GSK's key vaccines, Shingrix and Arexvy, in adults over 50 years of age, successfully achieving the study's primary goal.

$587 Million Valuation Doubts: BioAge Labs’ IPO Hides Crisis in Obesity Drug Market!

$587 Million Valuation Doubts: BioAge Labs’ IPO Hides Crisis in Obesity Drug Market!

2024-09-19

BioAge Labs, a biotechnology company focused on the field of obesity treatments, announced on Wednesday that it is seeking a valuation of up to $587 million in its U.S. initial public offering (IPO), according to regulatory filings.

Gavi Invests $50 Million to Purchase 500,000 Vaccine Doses, Pandemic Death Toll Exceeds 700, Global Health Emergency Alarm Sounds!

Gavi Invests $50 Million to Purchase 500,000 Vaccine Doses, Pandemic Death Toll Exceeds 700, Global Health Emergency Alarm Sounds!

2024-09-19

The Global Alliance for Vaccines and Immunization (Gavi) announced on Wednesday that it will procure 500,000 doses of a new smallpox vaccine produced by Bavarian Nordic.

$99 Monthly Fee! Hims & Hers Offers Discounts on Wegovy Weight Loss Drug to Specific Industry Patients, Market Shortage Intensifies, Who Will Protect Patient Rights?

$99 Monthly Fee! Hims & Hers Offers Discounts on Wegovy Weight Loss Drug to Specific Industry Patients, Market Shortage Intensifies, Who Will Protect Patient Rights?

2024-09-19

Hims & Hers says on its website that it is offering cimarlutide injections for $199 per month for patients on a 12-month plan.

Zantac Cancer Controversy Reignites, Jury Fails to Reach Verdict Again, 70,000 Lawsuits Pending!

Zantac Cancer Controversy Reignites, Jury Fails to Reach Verdict Again, 70,000 Lawsuits Pending!

2024-09-19

A man in Illinois claimed through his legal counsel that he had developed prostate cancer after taking a certain drug.

Coherus BioSciences Faces Digital Dilemma: Udenyca Supply Disruption Threatens Patient Access to Treatment

Coherus BioSciences Faces Digital Dilemma: Udenyca Supply Disruption Threatens Patient Access to Treatment

2024-09-18

Nearly a year after Coherus BioSciences' Udenyca syringes were rejected due to external manufacturing issues, a third-party manufacturer is once again troubling the California-based pharmaceutical company.

Generic Drug Giant Confirms Challenge to Novo Nordisk's High-Priced Ozempic for Under $100 Per Month, $150 Billion Market May Face Major Change!

Generic Drug Giant Confirms Challenge to Novo Nordisk's High-Priced Ozempic for Under $100 Per Month, $150 Billion Market May Face Major Change!

2024-09-18

The news is significant because Novo Nordisk CEO Lars Jorgensen is scheduled to appear next week before the Senate Health, Education, Labor and Pensions Committee (HELP), which Sanders chairs.

Daiichi Sankyo and Merck's New Drug Trial Faces Major Concerns, 586 Late-Stage Lung Cancer Patients Encounter New Challenges!

Daiichi Sankyo and Merck's New Drug Trial Faces Major Concerns, 586 Late-Stage Lung Cancer Patients Encounter New Challenges!

2024-09-18

On Tuesday, Daiichi Sankyo (4568.T) and Merck & Co (MRK.N) announced that its drug patritumab deruxtecan achieved its main goal in a clinical trial in advanced patients, extending the period of disease-free progression in some lung cancer patients.

2027 Drug Price Negotiation List Surprises! Novo Nordisk's Diabetes Drug Ozempic May Face Price Shock

2027 Drug Price Negotiation List Surprises! Novo Nordisk's Diabetes Drug Ozempic May Face Price Shock

2024-09-18

A senior executive at Danish pharmaceutical giant Novo Nordisk revealed that the company expects its diabetes drug Ozempic to be "highly likely" to be included in the U.S. government's list for drug price negotiations in 2027.

BeiGene Accused of Stealing Trade Secrets, AbbVie Sparks New Litigation Storm, BTK Degradant Research Stalls!

BeiGene Accused of Stealing Trade Secrets, AbbVie Sparks New Litigation Storm, BTK Degradant Research Stalls!

2024-09-18

Abbvie had filed an infringement lawsuit against Beigene in June last year, claiming that it infringed ibrutinib's patent rights.

41% of Fentanyl Samples in Los Angeles Contain Deadly Chemicals, 20 States Affected Nationwide

41% of Fentanyl Samples in Los Angeles Contain Deadly Chemicals, 20 States Affected Nationwide

2024-09-18

An industrial chemical used in plastic products has popped up in illegal drugs from California to Maine, a sudden and inexplicable shift in drug supply that has health researchers on alert.

China Accelerates Global Pharmaceutical Companies' Entry! China's NMPA Promotes New Drug Approval and International Trade Policies

China Accelerates Global Pharmaceutical Companies' Entry! China's NMPA Promotes New Drug Approval and International Trade Policies

2024-09-13

On September 13, Li Li, director of the State Medical Products Administration, made clear his support for open cooperation in the pharmaceutical industry at a high-profile press conference.

Eli Lilly Spends $1.8 Billion to Expand in Ireland, Crisis Lurking Behind Alzheimer's Disease Drug? 1,500 Jobs at Risk!

Eli Lilly Spends $1.8 Billion to Expand in Ireland, Crisis Lurking Behind Alzheimer's Disease Drug? 1,500 Jobs at Risk!

2024-09-13

Eli Lilly and Company announced it will invest $1.8 billion in two manufacturing sites in Ireland to boost production of its drugs for treating obesity and Alzheimer's disease.

Trillions in Investments Down the Drain? The Biotechnology Sector Faces a Cash Crisis, with Nearly 30% of Companies on the Brink of Survival

Trillions in Investments Down the Drain? The Biotechnology Sector Faces a Cash Crisis, with Nearly 30% of Companies on the Brink of Survival

2024-09-13

Pharmaceutical companies are investing up to $1 trillion in new biotech innovations.

How much do you know about medical talcum powder?

How much do you know about medical talcum powder?

2024-09-13

This article mainly introduces the application of medical talcum powder in the preparation process and its application as a pharmaceutical excipient.

GSK Vaccine Trial Breaks Through! Midterm Results Show Effectiveness Exceeds Standard Therapy, but Faces Patent Expiration Challenge

GSK Vaccine Trial Breaks Through! Midterm Results Show Effectiveness Exceeds Standard Therapy, but Faces Patent Expiration Challenge

2024-09-12

British pharmaceutical giant GlaxoSmithKline (GSK) has achieved encouraging mid-stage trial results for the seasonal flu vaccine program it is developing, the company announced in a statement released Thursday.

  • Pharmaceutical Industry Overview

    The magazine has been officially published in August 2024 and will be distributed at CPHI Korea 2024 and CPHI Milan 2024. It could be permanently available for download online. We sincerely invite you to join us in the publicity, making full use of the influence of the journal to promote your brand & products, expand your corporate influence in the global market.
    Published in: Aug. 2024

ECHEMI Partner

Complaint
Email:
Message:
Send Message